Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous bone marrow mononuclear cells for left ventricular dysfunction after myocardial infarction
2006-005628-17Phase 2Active
- Sponsor
- Grupo de Terapia Celular y Cardiovascular (HUCA)
- Start
- Feb 2007
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, single-blind trial of autologous bone marrow-derived mononuclear cell in myocardial infarction (MI), left ventricular systolic dysfunction (LVSD) and coronary arteriosclerosis (2 arms), sponsored by Grupo de Terapia Celular y Cardiovascular (HUCA). Primary endpoint: Improvement in left ventricular systolic function. Started Feb 2007; status: active.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
myocardial infarction (MI)left ventricular systolic dysfunction (LVSD)coronary arteriosclerosis
Beyond the preview
Go deeper on 2006-005628-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005628-17.